胰高血糖素样肽 1 受体激动剂与炎症性肠病患者回肠或肠梗阻风险增加无关--丹麦全国队列研究。

IF 4.5 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Inflammatory Bowel Diseases Pub Date : 2025-07-07 DOI:10.1093/ibd/izae276

Jan Nielsen, Sonia Friedman, Bente Mertz Nørgård, Torben Knudsen, Jens Kjeldsen, Mette Wod

{"title":"胰高血糖素样肽 1 受体激动剂与炎症性肠病患者回肠或肠梗阻风险增加无关--丹麦全国队列研究。","authors":"Jan Nielsen, Sonia Friedman, Bente Mertz Nørgård, Torben Knudsen, Jens Kjeldsen, Mette Wod","doi":"10.1093/ibd/izae276","DOIUrl":null,"url":null,"abstract":"Background: There is a global increase in the prevalence of obesity, including among individuals with inflammatory bowel disease (IBD). Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are potential anti-obesity medications due to their weight-lowering effects. However, concerns exist regarding ileus and intestinal obstruction as a severe side effect.Methods: This nationwide Danish cohort study evaluates the risk of ileus and intestinal obstruction in patients with IBD receiving GLP-1RAs. Patients with IBD and their exposure to GLP-1RAs were identified using Danish health registries. Cox regression analysis was used to estimate hazard ratios for the risk of ileus and intestinal obstruction adjusted for age at diagnosis of IBD, sex, type of IBD, prior ileus or intestinal obstruction, diabetes status, steroid use, and small bowel or colon surgery.Results: This study found that GLP-1RA exposure was not associated with an increased risk of ileus or intestinal obstruction in patients with IBD.Conclusion: This study suggests that GLP-1RAs do not increase the risk of ileus or intestinal obstruction in patients with IBD.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1961-1965"},"PeriodicalIF":4.5000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Glucagon-Like Peptide 1 Receptor Agonists Are Not Associated With an Increased Risk of Ileus or Intestinal Obstruction in Patients with Inflammatory Bowel Disease-A Danish Nationwide Cohort Study.\",\"authors\":\"Jan Nielsen, Sonia Friedman, Bente Mertz Nørgård, Torben Knudsen, Jens Kjeldsen, Mette Wod\",\"doi\":\"10.1093/ibd/izae276\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: There is a global increase in the prevalence of obesity, including among individuals with inflammatory bowel disease (IBD). Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are potential anti-obesity medications due to their weight-lowering effects. However, concerns exist regarding ileus and intestinal obstruction as a severe side effect.Methods: This nationwide Danish cohort study evaluates the risk of ileus and intestinal obstruction in patients with IBD receiving GLP-1RAs. Patients with IBD and their exposure to GLP-1RAs were identified using Danish health registries. Cox regression analysis was used to estimate hazard ratios for the risk of ileus and intestinal obstruction adjusted for age at diagnosis of IBD, sex, type of IBD, prior ileus or intestinal obstruction, diabetes status, steroid use, and small bowel or colon surgery.Results: This study found that GLP-1RA exposure was not associated with an increased risk of ileus or intestinal obstruction in patients with IBD.Conclusion: This study suggests that GLP-1RAs do not increase the risk of ileus or intestinal obstruction in patients with IBD.\",\"PeriodicalId\":13623,\"journal\":{\"name\":\"Inflammatory Bowel Diseases\",\"volume\":\" \",\"pages\":\"1961-1965\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Inflammatory Bowel Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ibd/izae276\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammatory Bowel Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ibd/izae276","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：全球肥胖症发病率正在上升，其中包括炎症性肠病（IBD）患者。胰高血糖素样肽1受体激动剂（GLP-1RAs）具有降低体重的作用，是潜在的抗肥胖药物。然而，回肠和肠梗阻作为一种严重的副作用令人担忧：这项全国性的丹麦队列研究评估了接受 GLP-1RAs 治疗的 IBD 患者发生回肠和肠梗阻的风险。IBD患者及其GLP-1RAs暴露情况通过丹麦健康登记处进行确认。采用 Cox 回归分析估计回肠和肠梗阻风险的危险比，并根据诊断 IBD 时的年龄、性别、IBD 类型、既往回肠或肠梗阻情况、糖尿病状况、类固醇使用情况以及小肠或结肠手术情况进行调整：结果：研究发现，IBD 患者接触 GLP-1RA 与回肠或肠梗阻风险增加无关：本研究表明，GLP-1RA 不会增加 IBD 患者发生回肠梗阻或肠梗阻的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Glucagon-Like Peptide 1 Receptor Agonists Are Not Associated With an Increased Risk of Ileus or Intestinal Obstruction in Patients with Inflammatory Bowel Disease-A Danish Nationwide Cohort Study.

Background: There is a global increase in the prevalence of obesity, including among individuals with inflammatory bowel disease (IBD). Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are potential anti-obesity medications due to their weight-lowering effects. However, concerns exist regarding ileus and intestinal obstruction as a severe side effect.

Methods: This nationwide Danish cohort study evaluates the risk of ileus and intestinal obstruction in patients with IBD receiving GLP-1RAs. Patients with IBD and their exposure to GLP-1RAs were identified using Danish health registries. Cox regression analysis was used to estimate hazard ratios for the risk of ileus and intestinal obstruction adjusted for age at diagnosis of IBD, sex, type of IBD, prior ileus or intestinal obstruction, diabetes status, steroid use, and small bowel or colon surgery.

Results: This study found that GLP-1RA exposure was not associated with an increased risk of ileus or intestinal obstruction in patients with IBD.

Conclusion: This study suggests that GLP-1RAs do not increase the risk of ileus or intestinal obstruction in patients with IBD.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Inflammatory Bowel Diseases 医学-胃肠肝病学

CiteScore

9.70

自引率

6.10%

发文量

462

审稿时长

1 months

期刊介绍： Inflammatory Bowel Diseases® supports the mission of the Crohn''s & Colitis Foundation by bringing the most impactful and cutting edge clinical topics and research findings related to inflammatory bowel diseases to clinicians and researchers working in IBD and related fields. The Journal is committed to publishing on innovative topics that influence the future of clinical care, treatment, and research.